Last reviewed · How we verify

Patients- dose titration

Institute of Psychiatry, London · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Patients- dose titration is a Small molecule drug developed by Institute of Psychiatry, London. It is currently FDA-approved.

ZG0895 Hydrochloride for Injection is a small molecule being studied in a Phase 1 clinical trial for its potential efficacy in treating advanced solid tumors. The study is investigating the tolerability, safety, pharmacokinetics, and pharmacodynamics of ZG0895 Hydrochloride for Injection, with cotinine being a 15% component of the dose.

At a glance

Generic namePatients- dose titration
SponsorInstitute of Psychiatry, London
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Patients- dose titration

What is Patients- dose titration?

Patients- dose titration is a Small molecule drug developed by Institute of Psychiatry, London.

Who makes Patients- dose titration?

Patients- dose titration is developed and marketed by Institute of Psychiatry, London (see full Institute of Psychiatry, London pipeline at /company/institute-of-psychiatry-london).

What development phase is Patients- dose titration in?

Patients- dose titration is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing